Endo Pharmaceuticals to Pay $180M in a Licensing and Development Agreement for BioDelivery Sciences International Pain Treatment

Abby Callard -   Print  |
Endo Pharmaceuticals will pay up to $180 million, plus royalties, to BioDelivery Sciences International in a licensing and development agreement to manufacture, distribute, market and sell BEMA Buprenorphine on a global scale, according to a MarketWatch report. The drug is currently in phase 3 trials and treats moderate to severe chronic pain by applying a small piece of polymer film to the inner lining of the cheek. The film eventually dissolves.

Related Articles on Pain Management:
Spinal Manipulation More Effective for Neck Pain Than Medication
Arcion Receives U.S. Patent for Topical Therapy for Chronic Pain
5 Ways to Safeguard Against Opioid Abuse and Diversion From Robert Saenz, CEO of Tulsa Pain Consultants

© Copyright ASC COMMUNICATIONS 2021. Interested in LINKING to or REPRINTING this content? View our policies here.

Featured Webinars

Featured Whitepapers